doi: 10.1517/13543784.2011.630660 13 GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art - PubMed
Mounjaro delivers consistent outcomes and has a more extensive history
Retatrutide for type 2 diabetes: Phase 2 trial results (36-week study, HbA1c reductions, weight loss) New England Journal of Medicine (2023) Jastreboff AM, et al
We Handle All Medicare Eligibility & Coverage Checks No more calling insurance or sitting on hold, we handle everything: Plan formulary checks Diagnosis eligibility Prior authorizations Alternative coverage pathways Out-of-pocket estimates You only proceed when you clearly understand your coverage
For instance, proponents argue GLP-1 coverage can reduce incidents of diabetes and cardiovascular events (as clinical trials suggest)
Prior to the advent of glucagon-like peptide- 1 receptor agonist (GLP-1RA) therapy with liraglutide in 2014, these medications made up most prescriptions for weight loss medications [2]
